The assessment of activity of anti-angiogenic agents in advanced angiosarcoma makes sense, since the phenotype of this sarcoma and the frequent occurrence of KDR mutations (74), involving in the angiogenic signaling pathways. The gene discussed is KDR; the disease is sarcoma.